Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" β-thalassemia major patients

American Journal of Hematology

Volumn 85, Issue 6, 2010, Pages 460-461

  Balocco, Manuela ^a   Carrara, Paola ^a   Pinto, Valeria ^a   Forni, Gian Luca ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; ARTHRALGIA; BETA THALASSEMIA; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HIP PAIN; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY DISEASE; KNEE PAIN; LETTER; LIVER LEVEL; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; SKIN MANIFESTATION; SPLENECTOMY; THALASSEMIA MAJOR;

ADMINISTRATION, ORAL; ARTHRALGIA; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; TRIAZOLES; YOUNG ADULT;

EID: 77953069934     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21711     Document Type: Letter

References (4)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193. (Pubitemid 39390442)
2. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82(12 Suppl):1136-1139. (Pubitemid 350221244)
3. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-1465. (Pubitemid 41129616)
4. Wood JC. Diagnosis and management of transfusion iron overload: The role of imaging. Am J Hematol 2007;82(12 Suppl):1132-1135. (Pubitemid 350221243)